PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	09/936,957
Filing Date	September 17, 2001
First Named Inventor	Meikle
Art Unit	1641
Examiner Name	Unassigned
Attorney Docket Number	021385-014010US

U.S. PATENT DOCUMENTS

Examiner	Cite No.[1]	Document Number: Number Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]	Number[4]	Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	AA	AU	29906/92	A	06-10-1993			☐
	AB	AU	26869/97	A	11-27-1997			☐
								☐
								☐
								☐
								☐
								☐
								☐

Examiner Signature		Date Considered	5/21/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] **Applicant's** unique citation designation number **(optional)**. [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete If Known	
Application Number	09/936,957
Filing Date	September 17, 2001
First Named Inventor	Meikle
Art Unit	1641
Examiner Name	Unassigned
Attorney Docket Number	021385-014010US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	AC	ALEXANDER et al., "5 Related Lebanese Individuals with high Plasma Lysosomal Hydrolases A New Defect in Mannose-6-Phosphate Receptor Recognition," Am. J. Human Genetics, 36(5):1001-1014 (1984).	
	AD	BROOKS et al., "Immunoquantification of the Low Abundance Lysosomal Enzyme N-acetylgalactosamine 4-sulphatase," J. Inherited Metabolic Disease, 13(1):108-120 (1990).	
	AE	GATTI et al., "Comparative Study of 15 Lysosomal Enzymes in Chorionic Villi and Cultured Amniotic Fluid Cells. Early Prenatal Diagnosis in Seven Pregnancies at Risk for Lysosomal Storage Diseases," Prenatal Diagnosis, 5(5):329-336 (1985).	
	AF	GRIFFITHS et al., "Plasma Acid Hydrolases in Normal Adults and Children, and in Patients with Some Lysosomal Storage Diseases," Clinical Chimica Acta: Int. J. of Clinical Chemistry, 90(2):129-141 (1978).	
	AG	HUA et al., "Evaluation of the Lysosome-Associated Membrane Protein LAMP-2 as a Marker for Lysosomal Storage Disorders," Clinical Chemistry, 44(10):2094-2102 (1998).	
	AH	KLEIMAN et al., "Sandhoff Disease in Argentina: High Frequency of a Splice Site Mutation in the HEXB Gene and Correlation Between Enzyme and DNA-Based Tests for Heterozygote Detection," Human Genetics, 94:279-282 (1994).	
	AI	LOVELL et al., "Biochemical and Histochemical Analysis of lysosomal Enzyme Activities in Caprine Beta-Mannosidosis," Molecular and Chemical Neuropathology, 21(1):61-74 (1994).	
	AJ	McCABE et al., "Preferential Inhibition of Lysosomal Beta Mannosidase by Sucrose," Enzyme, 43(3):137-145 (1990).	
	AK	O'BRIAN et al., "Saposin proteins: structure, function, and role in human lysosomal disorders," FASEB J., 5(3):301-308 (1991).	
	AL	PRENCE et al., "Diagnosis of Alpha Mannosidosis by Measuring Alpha Mannosidase in Plasma," Clinical Chemistry, 38(4):501-503 (1992).	
	AM	TAGER, J.M., "Biosynthesis and deficiency of lysosomal enzymes," TIBS, 10(8):324-326 (1985)	
	AN	WHITLEY et al., "Long-term Outcome of Hurler Syndrome Following Bone Marrow Transplantation," Am. J. Medical Genetics, 46(2):209-218 (1993).	
	AO	YAMAGUCHI et al., "Improvement of Tear Lysosomal Enzyme Levels After Treatment with Bone Marrow Transplantation in a Patient with I-Cell Disease," Opthalmic Research, 21(3):226-229 (1989).	
	AP	YUFENG et al., "Elevated Plasma Chitotriosidase Activity In Various Lysosomal Storage Disorders," J. Inherited Metabolic Disease, 18(6):717-722 (1995).	

Examiner Signature		Date Considered	5/31/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.